This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Tuesday, May 21, 2013
DDW 2013 Video - Simeprevir (Tmc435) Plus Sofosbuvir (Gs-7977) With or Without Ribavirin HCV GT 1 Null Responders.
DDW 2013 Late Breaker
Eric J. Lawitz, MD discusses his late-breaking poster: Sa2073: Svr4 Results of a Once Daily Regimen of Simeprevir (Tmc435) Plus Sofosbuvir (Gs-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders. Dr. Lawitz is Medical Director, principal investigator for Alamo Medical research
http://www.healio.com/hepatology.
No comments:
Post a Comment